Multiple Sclerosis Walking Scale-12 (MSWS-12)
Also known as: MS Walking Scale-12, MSWS
The MSWS-12 is a brief, patient-reported outcome measure specifically designed to assess the impact of multiple sclerosis on walking ability and limitation. Developed by Hobart and colleagues in 2003, this 12-item scale captures both the physical difficulty and functional consequences of MS-related gait impairment. It is highly responsive to change and widely used in MS clinical trials and practice as a primary outcome measure for assessing intervention effects on mobility.
Key highlights
- Extremely brief (12 items, 3-5 minutes) and practical for routine clinical use and serial monitoring without substantial respondent burden
- Highly responsive to change—sensitive to detecting meaningful improvements in walking with rehabilitation or treatment
- Strong psychometric properties: demonstrated validity, reliability, and minimal floor/ceiling effects in diverse MS populations across disease courses
- Patient-centered measurement captures subjective walking experience and functional limitation beyond objective gait speed
- Widely adopted in MS research and clinical practice worldwide; extensively translated and validated in multiple languages
Intuition
This section is available to Pro members. Upgrade to Pro
How it works
This section is available to Pro members. Upgrade to Pro
When to use it
MSWS-12 is ideal when brief assessment of MS walking impact is needed: clinical trials of therapies targeting mobility (rehabilitation, exercise, walking-specific treatments), routine clinical monitoring in MS clinics to track walking-related disability, longitudinal cohort studies examining predictors of walking decline, comparative effectiveness research of mobility interventions, and patient-reported outcomes surveillance. It complements objective gait measures (Timed 25-Foot Walk, 6-Minute Walk Test) by capturing subjective walking experience. It is less suitable when non-walking MS patients must be assessed (use broader QoL scales like MSQOL-54 instead) or when only objective gait speed is the outcome of interest.
Strengths & limitations
- Extremely brief (12 items, 3-5 minutes) and practical for routine clinical use and serial monitoring without substantial respondent burden
- Highly responsive to change—sensitive to detecting meaningful improvements in walking with rehabilitation or treatment
- Strong psychometric properties: demonstrated validity, reliability, and minimal floor/ceiling effects in diverse MS populations across disease courses
- Patient-centered measurement captures subjective walking experience and functional limitation beyond objective gait speed
- Widely adopted in MS research and clinical practice worldwide; extensively translated and validated in multiple languages
- Scores range 0-100 with higher=worse, which is opposite to most QoL scales and can be counterintuitive; scoring transformation must be applied correctly
- Not suitable for non-ambulatory MS patients (cannot walk at baseline); does not measure wheelchair/assistive device use experience
- May show ceiling effect in very early MS with minimal walking limitation (many score near 0)
- Unidimensional structure means it does not differentiate causes of limitation (e.g., weakness vs. spasticity vs. fatigue); supplements with targeted examination needed
Common pitfalls
This section is available to Pro members. Upgrade to Pro
Applications
This section is available to Pro members. Upgrade to Pro
Frequently asked
Does a high MSWS-12 score mean good walking or bad walking?
High MSWS-12 score means WORSE walking limitation. On the 0-100 scale, 0-20 = minimal limitation (good), 81-100 = very severe limitation (bad). This is opposite to most QoL scales (e.g., MSQOL-54, SF-36) where high=better. Always check the scale direction when comparing measures.
How much MSWS-12 change is clinically meaningful?
A change of 4-5 points on the 0-100 scale is considered the minimal clinically important difference (MCID). So an improvement (decrease) from baseline 50 to 45 is meaningful; a change to 48 might not be. In clinical trials, effect sizes and between-group differences are more informative than individual point changes.
Should I use MSWS-12 or Timed 25-Foot Walk test?
MSWS-12 measures patient-perceived walking limitation; Timed 25-Foot Walk measures objective gait speed. Both are valuable and often used together: T25FW for objective impairment, MSWS-12 for subjective impact. Some patients with slow gait report minimal limitation; others with faster gait report substantial limitation. Both capture important aspects. Use MSWS-12 for clinical monitoring of QoL impact; use T25FW to objectively track gait speed changes.
Can MSWS-12 be used in wheelchair-using MS patients?
No. MSWS-12 measures walking limitation experience and is designed for patients who walk (with or without assistive devices). For non-ambulatory patients, use broader MS QoL scales (MSQOL-54) or wheelchair-specific mobility measures. If a patient transitions from walking to wheelchair during longitudinal follow-up, MSWS-12 becomes inapplicable after that transition; switch to alternative measures at that point.
Sources
- 1.Hobart, J. C., Riazi, A., Lamping, D. L., Fitzpatrick, R., & Thompson, A. J. (2003). Measuring the impact of MS on walking ability: The 12-Item MS Walking Scale (MSWS-12). Neurology, 60(1), 31-36.
You have read it. What now?
Cite this page
ScholarGate. (2026, June 3). MSWS-12. ScholarGate. https://scholargate.app/neurology/msws-12